Tandem Diabetes Care, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tandem Diabetes Care, Inc.
After more than three years of treating the Tandem Diabetes Care Control-IQ Technology system as moderate-risk class II, the US FDA has made the designation official. The classification will also apply to future similar devices.
In an interview with Medtech Insight following the J.P. Morgan Health Care Conference, Dexcom CEO Kevin Sayer discussed marketing plans for the next-generation G7 continuous glucose monitoring system and for the simpler CGM, Dexcom One, and outlined plans ahead.
Dexcom is making CGM data available through consumer devices starting with Garmin’s smartwatches and bicycle computers.
In an interview with Medtech Insight, Dexcom CEO Kevin Sayer discussed his views on the blood glucose measurement market, how he thinks it will change, and Dexcom’s responsibilities to patients, regulators and payors.
- Drug Delivery
- Monitoring Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
In Vitro Diagnostics
- Glucose Testing